Literature DB >> 11739143

Airway inflammation is present during clinical remission of atopic asthma.

L M van den Toorn1, S E Overbeek, J C de Jongste, K Leman, H C Hoogsteden, J B Prins.   

Abstract

Symptoms of atopic asthma often disappear at puberty. However, asthmatic subjects in clinical remission will frequently have a relapse later in life. The aim of this study was to investigate whether subjects in clinical remission of atopic asthma have persistent airway inflammation and/or airway remodeling. Bronchial biopsies were obtained from subjects in clinical remission, asthmatic subjects, and healthy control subjects. The presence and/or activation state of eosinophils, mast cells, macrophages, T lymphocytes, interleukin (IL)-5, eotaxin, and inducible nitric oxide synthase (iNOS) were analyzed. Results were compared with less invasive indicators of airway inflammation. Also aspects of airway remodeling were determined. Eosinophils, T cells, mast cells, and IL-5 were significantly elevated in the airway mucosa of subjects in remission compared with control subjects. Also, blood eosinophil cell counts were significantly higher in subjects in clinical remission. Blood eosinophil cell counts, exhaled nitric oxide (eNO) levels, and bronchial response to adenosine-5'-monophosphate correlated significantly with the quantity of tissue eosinophils. Significant airway remodeling was found in subjects in clinical remission. Our study has shown ongoing airway inflammation and airway remodeling in adolescents in clinical remission of atopic asthma. Subclinical airway inflammation may well determine the risk of an asthma relapse later in life.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739143     DOI: 10.1164/ajrccm.164.11.2006165

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  60 in total

1.  Airway inflammation in children with difficult asthma: relationships with airflow limitation and persistent symptoms.

Authors:  D N R Payne; Y Qiu; J Zhu; L Peachey; M Scallan; A Bush; P K Jeffery
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

2.  Pediatric Respiratory Assembly. Mini symposium on lung inflammation.

Authors:  Larry C Lands; A Keith Tanswell; Sophie Laberge; Christine McCusker; Felix Ratjen
Journal:  Can Respir J       Date:  2010 Mar-Apr       Impact factor: 2.409

Review 3.  Role of interleukin-13 in asthma.

Authors:  Jonathan Corren
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

4.  Childhood factors associated with asthma remission after 30 year follow up.

Authors:  J M Vonk; D S Postma; H M Boezen; M H Grol; J P Schouten; G H Koëter; J Gerritsen
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

5.  Blocking cyclophilins in the chronic phase of asthma reduces the persistence of leukocytes and disease reactivation.

Authors:  Erik J Stemmy; Molly A Balsley; Rosalyn A Jurjus; Jesse M Damsker; Michael I Bukrinsky; Stephanie L Constant
Journal:  Am J Respir Cell Mol Biol       Date:  2011-04-14       Impact factor: 6.914

Review 6.  Epidemiology of stress and asthma: from constricting communities and fragile families to epigenetics.

Authors:  Rosalind J Wright
Journal:  Immunol Allergy Clin North Am       Date:  2011-02       Impact factor: 3.479

Review 7.  The paradox of adult asthma control: "who's in control anyway?".

Authors:  Rick Hodder
Journal:  Can Respir J       Date:  2007 May-Jun       Impact factor: 2.409

Review 8.  Overcoming gaps in the management of asthma in older patients: new insights.

Authors:  Pranoy Barua; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 9.  Exhaled nitric oxide: a test for diagnosis and control of asthma?

Authors:  Rohit Katial; Lora Stewart
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

Review 10.  Perinatal stress and early life programming of lung structure and function.

Authors:  Rosalind J Wright
Journal:  Biol Psychol       Date:  2010-01-18       Impact factor: 3.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.